BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

Phase 2

Completed

Conditions: Acute Decompensated Heart Failure

Interventions: Drug: BMS-986259
Other: Placebo

First Posted Date: 2020-03-23

Last Posted Date: 2022-08-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 25

Registration Number: NCT04318093

Locations: 🇦🇷
Local Institution - 0025, Cordoba, Argentina
🇦🇷
Local Institution - 0009, Ciudad de Buenos Aires, Buenos Aires, Argentina
🇬🇷
Local Institution - 0022, Athens, Greece

and more 11 locations

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

Phase 1

Terminated

Conditions: Tumor

Interventions: Drug: ipilimumab
Drug: ENHANZE (rHuPH20)
Drug: nivolumab

First Posted Date: 2020-03-17

Last Posted Date: 2023-02-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 21

Registration Number: NCT04311710

Locations: 🇳🇿
Local Institution - 0010, Auckland, New Zealand
🇺🇸
Local Institution - 0013, Fort Wayne, Indiana, United States
🇮🇹
Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapie, Napoli, Italy

and more 3 locations

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Phase 2

Completed

Conditions: Pulmonary Fibrosis

Interventions: Drug: BMS-986278
Other: BMS-986278 Placebo

First Posted Date: 2020-03-16

Last Posted Date: 2023-10-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 399

Registration Number: NCT04308681

Locations: 🇨🇳
Local Institution - 0175, Taipei, Taiwan
🇦🇺
Local Institution - 0021, Murdoch, Western Australia, Australia
🇬🇧
Local Institution, London, United Kingdom

and more 101 locations

A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165 Tablet formulation 1
Drug: BMS-986165 Tablet formulation 2

First Posted Date: 2020-03-12

Last Posted Date: 2021-11-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT04305899

Locations: 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States

Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants

Phase 1

Withdrawn

Conditions: Healthy Participants

Interventions: Drug: BMS-986235 (Treatment A)
Drug: Rifampin (Treatment B)

First Posted Date: 2020-03-10

Last Posted Date: 2022-03-31

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT04301310

Locations: 🇺🇸
Local Institution, Salt Lake City, Utah, United States

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Drug: Milk of magnesia

First Posted Date: 2020-02-13

Last Posted Date: 2022-01-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT04269356

Locations: 🇺🇸
Covance - Clinical Pharmacology Services - Madison, Madison, Wisconsin, United States

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

Phase 2

Terminated

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Drug: BMS-986263
Other: Placebo

First Posted Date: 2020-02-12

Last Posted Date: 2024-02-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 124

Registration Number: NCT04267393

Locations: 🇺🇸
Local Institution - 0150, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0171, Dallas, Texas, United States
🇺🇸
Local Institution - 0143, Redwood City, California, United States

and more 99 locations

A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Atazanavir/Cobicistat
Drug: Reyataz Atazanavir
Drug: Cobicistat

First Posted Date: 2020-02-10

Last Posted Date: 2021-11-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 34

Registration Number: NCT04263350

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165 prototype 2
Drug: BMS-986165 prototype 1
Drug: BMS-986165

First Posted Date: 2020-01-30

Last Posted Date: 2020-04-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT04249284

Locations: 🇺🇸
Quotient Sciences Miami, Miami, Florida, United States

A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function

Phase 1

Completed

Conditions: Renal Failure

Interventions: Drug: BMS-986259

First Posted Date: 2020-01-23

Last Posted Date: 2021-09-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT04237831

Locations: 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Prism Clinical Research, Saint Paul, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy